

Ontario Public Drug Programs

Drug Submission Status

Report for September 2017

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Erlotinib	Tarceva	erlotinib	25mg	FC tablet	02461862
Apotex Inc.	Apo-Erlotinib	Tarceva	erlotinib	100mg	FC tablet	02461870
Apotex Inc.	Apo-Erlotinib	Tarceva	erlotinib	150mg	FC tablet	02461889
Apotex Inc.	Apo-Gefitinib	Iressa	gefitinib	250mg	coated tablet	02468050
Jamp Pharma Corporation	Jamp-Cetirizine	Reactine	cetirizine HCl	20mg	FC tablet	02466171